Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
Teva Neuroscience, Inc. presented results from a clinical pharmacology study in which AZILECT(R) (rasagiline tablets) did not increase the risk of tyramine sensitivity at the maximum approved dose of 1 mg. The presentation was made during the 13th International Congress of Parkinson"s Disease and Movement Disorders in Paris, France. This study assessed the potential risk of hypertensive crisis due to the interaction between high doses of oral tyramine and therapeutic doses of rasagiline, which is indicated both as monotherapy in patients with early Parkinson"s disease (PD) and as adjunctive treatment in patients receiving levodopa. The study supported the selectivity of rasagiline for inhibition of MAO-B at currently approved doses.
generic viagra online
Scientists Counteract Nanoparticle Lung Damage In Mice
Scientists have identified for the first time a mechanism by which nanoparticles cause lung damage and have demonstrated that it can be combated by blocking the process involved, taking a step toward addressing the growing concerns over the safety of nanotechnology.
News of the day
Benefit To Women Not Enough To Sway Men To Get HPV Vaccine
Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.
Mental Health

Frankenman International Ltd Secures FDA Clearance For Its Entire CHEX Range Of Surgical Staplers

Frankenman International Ltd, the manufacturer and supplier of surgical instruments, announced that its entire CHEX™ range of surgical staplers had been granted FDA approval. This development complements the CE and ISO accreditation it has already acquired. FDA approval endorses Frankenman"s commitment to total quality in surgical stapling and wound closure devices, and further validates its position as a trusted alternative supplier in these markets. Having established itself in Europe and many other international markets, Frankenman International Ltd now plans to expand marketing of the CHEX range into Japan, Australia and Korea by the end of 2009. This will enable more patients and hospitals around the world to benefit from its cost-effective range of surgical instruments. "We are delighted to have secured FDA registration as this globally recognised quality mark will further strengthen surgeons" confidence in our CHEX range of surgical staplers and establish Frankenman International as a credible player," comments Lee Edwards, President of International Business at Frankenman International Ltd. "With a well established, professional and successful distribution network in place, we are now concentrating on strategic growth by accelerating our internal and external R & D programmes so that we can bring even more innovative instruments to our customers in the coming years." Frankenman International Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009